Download PDF
Drug Res (Stuttg) 2016; 66(02): 100-106
DOI: 10.1055/s-0035-1554631
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacokinetics of Oral Combination Contraceptive Drugs Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Chinese Volunteers

X. Xin
1   Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China
,
Y. Wu
1   Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China
,
X. Liu
1   Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China
,
C. Sun
1   Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China
,
T. Geng
1   Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China
,
L. Ding
1   Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, China
2   Nanjing Clinical Tech laboratories Inc., Nanjing, China
› Author Affiliations
Further Information

Publication History

received 29 January 2015

accepted 08 May 2015

Publication Date:
02 June 2015 (online)

Also available at
    Permissions and Reprints

Abstract

Background and Objective: A new combination contraceptive tablet containing 0.02 mg ethinyl estradiol (EE) and 0.10 mg levonorgestrel (LNG) with potential advantages has been developed in China. This study was aimed to describe the pharmacokinetic characteristics of this new combination contraceptive tablet in female Chinese volunteers.

Methods: This study was designed as phase I, open-label, and one-sequence clinical trial. 12 healthy nonpregnant female Chinese volunteers received a single dose (1 tablet) and multiple dose (1 tablet per day) administration for 21 consecutive days under fasting condition. Blood samples were analyzed with 2 validated LC-MS/MS methods for EE and LNG, respectively.

Results and conclusion: After the single dose administration, the C max of EE and LNG were 44.76±18.64 pg/mL and 2.256±1.008 ng/mL, respectively. The steady-state condition of EE was achieved on the 6th day after the beginning of the multiple dose administration, while the steady-state condition of LNG was achieved on the 21st day. For EE, the mean MRT 0–72 and t 1/2 increased by 40.2 and 30.6%, meanwhile the mean Cl/F and Vd/F decreased by 18.5 and 29.1%, respectively from Day 1 to Day 24. For LNG, the mean MRT 0–72 increased by 27.1%, while the mean Cl/F and Vd/F decreased by 62.4 and 86.3%, respectively from Day 1 to Day 24. The t 1/2 remained unchanged for LNG. The exposure of LNG significantly increased with repeated dosing, but that of EE just slightly increased.

Key words

ethinyl estradiol - levonorgestrel - LC-MS/MS - pharmacokinetics - sex hormone-binding globulins
 

  • References

  • 1 Bonn M, Eydeler U, Barkworth M et al. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers. Arzneimittelforschung 2009; 59: 651-658
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 FDA, Available at www.accessdata.fda.gov/drugsatfda_docs/label/2008/020683s004s006s007lbl.pdf
    PubMed
  • 3 Boyd RA, Zegarac EA, Posvar EL et al. Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol. Contraception 2001; 63: 71-76
    CrossrefPubMedGoogle Scholar
  • 4 Kuhnz W, Gansau C, Fuhrmeister A. Pharmacokinetics of gestodene in 12 women who received a single oral dose of 0.075 mg gestodene and, after a wash-out phase, the same dose during one treatment cycle. Contraception 1992; 46: 29-40
    CrossrefPubMedGoogle Scholar
  • 5 Saperstein S, Edgren RA, Lee GJL et al. Bioequivalence of two oral contraceptive drugs containing norethindrone and ethinyl estradiol. Contraception 1989; 40: 581-590
    CrossrefPubMedGoogle Scholar
  • 6 Cherala G, Pearson J, Maslen C et al. An Ethinyl Estradiol-Levonorgestrel Containing Oral Contraceptive Does Not Alter Cytochrome P4502C9 In Vivo Activity. Drug Metab Dispos 2014; 42: 323-325
    CrossrefPubMedGoogle Scholar
  • 7 Kulier R, Helmerhorst FM, Maitra N et al. Effectiveness and acceptability of progestogens in combined oral contraceptives – a systematic review. Reprod Health 2004; 1: 1
    CrossrefPubMedGoogle Scholar
  • 8 Orme M, Back DJ, Ward S et al. The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. Contraception 1991; 43: 305-316
    CrossrefPubMedGoogle Scholar
  • 9 Available at http://www.drugs.com/pro/levlite.html
    PubMed
  • 10 Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception 2013; 87: 706-727
    CrossrefPubMedGoogle Scholar
  • 11 DelConte A, Loffer F, Grubb GS. Original Research Articles – Cycle Control With Oral Contraceptives Containing 20 mg of ethinyl estradiol: A Multicenter, Randomized Comparison of Levonorgestrel/Ethinyl Estradiol (100 mg/20mg) and. Contraception 1999; 59: 187-194
    CrossrefPubMedGoogle Scholar
  • 12 PhD IM, MD CHG . Assessment of drug accumulation in the evaluation of pharmacokinetic data. J Clin Pharmacol 1998; 38: 680-684
    CrossrefPubMedGoogle Scholar
  • 13 Back D, Breckenridge A, Challiner M et al. The effect of antibiotics on the enterohepatic circulation of ethinylestradiol and norethisterone in the rat. J Steroid Biochem 1978; 9: 527-531
    CrossrefPubMedGoogle Scholar
  • 14 Orme MLE, Back DJ. Factors affecting the enterohepatic circulation of oral contraceptive steroids. Am J Obstet Gynecol 1990; 163: 2146-2152
    CrossrefPubMedGoogle Scholar
  • 15 DiLiberti CE, O’Leary CM, Hendy CH et al. Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen. Contraception 2011; 83: 55-61
    CrossrefPubMedGoogle Scholar